All In Biotech

Drug Trial Radar · NCT05135663

Extension Study of NS-089/NCNP-02 in DMD

A Phase II, Open-Label, Extension Study of NS-089/NCNP-02 in Patients With Duchenne Muscular Dystrophy

Last checked: Nov 19, 2026Latest source record: Jul 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

6

Actual

Start

Jun 23, 2021

Primary completion

Apr 30, 2027

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Nippon Shinyaku Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is the extension study of NS-089/NCNP-02 (Study NCNP/DMT02), which is designed to assess the safety, tolerability and efficacy of NS-089/NCNP-02 in patients with Duchenne muscular dystrophy (DMD).

Conditions

  • Duchenne Muscular Dystrophy (DMD)

Interventions

  • NS-089/NCNP-02Drug

    The same dose administered in as Part 2 of Study NCNP/DMT02 (40 mg/kg) will be administered once weekly for 288 weeks (The total treatment period is 312 weeks including Part2 of Study NCNP/DMT02).

  • NS-089/NCNP-02Drug

    The same dose administered in as Part 2 of Study NCNP/DMT02 (80 mg/kg) will be administered once weekly for 288 weeks (The total treatment period is 312 weeks including Part2 of Study NCNP/DMT02).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: Up to Week 319

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Kagoshima University Hospital

    Kagoshima, Japan

  • National Center of Neurology and Psychiatry

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.